Furthermore, rather than relying solely on single-agent strategies, insights from omics are progressively driving the creation of combination therapies designed to characterize treatment resistance and improve patient outcomes by investigating synergistic combinations, such as AR inhibition paired with DDR-targeted therapies or immunotherapy approaches to address tumor adaptability and the immunosuppressive microenvironment present within tumors [38]. Here, AR is linked to neoplasm.